Dosing has begun in a new regimen of the HEALEY ALS platform trial, its ninth, which is testing the oral therapy NUZ-001 for ...
When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...
The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
Four investigational ALS treatments failed in phase II studies, but CNM-Au8 and pridopidine showed promising trends. The platform trial pooled placebo data across studies, allowing more ALS patients ...
A new study demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results